Eskalith
Eskalith (lithium carbonate) is an antimanic agent indicated in the treatment of manic episodes of manic-depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania.
Dosage by Body Weight
Dosage must be individualized according to serum lithium levels and clinical response. For acute mania, the typical dose is 1,800 mg/day divided into 3 or 4 doses. For maintenance therapy, the typical dose is 900 mg to 1,200 mg/day divided into 3 or 4 doses. Continuous monitoring of serum lithium concentrations is mandatory.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients under 12 years of age have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients under 12 years of age have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients under 12 years of age have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients under 12 years of age have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients under 12 years of age have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients under 12 years of age have not been established. |
| 5-7 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients under 12 years of age have not been established. |
| 8-10 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients under 12 years of age have not been established. |
| 11-15 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients under 12 years of age have not been established. |
| 16-20 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients under 12 years of age have not been established. |
Formulation
Purpose
Treatment and prophylaxis of manic episodes in bipolar disorder (manic-depressive illness).
Generic Name
Lithium CarbonateScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.